BOLDER BIOTECHNOLOGY GETS $1.6 MIL NIH GRANT FOR MS DRUG.Bolder BioTechnology, Inc., Boulder. Colo., has been awarded a $1.6 million Phase II Continuing Renewal Small Business Innovation Research (SBIR SBIR Small Business Innovation Research (program/grant) SBIR Space Based Infra-Red SBIR Speaker-Boundary Interference SBIR Site Backsurface-referenced Ideal Plane/Range (silicon wafers) ) grant, entitled "Long-Acting Beta Interferon for Multiple Sclerosis", from the National Institute of Neurological Disorders and Stroke The National Institute of Neurological Disorders and Stroke is a part of the U.S. National Institutes of Health. The NINDS conducts and supports research on brain and nervous system disorders. Created by the U.S. (NINDS NINDS Neurology A multicenter, double blinded, randomized trial–National Institute of Neurological Disorders and Stroke which evaluated the effects of tPA therapy in Pts with stroke. See Thrombolytic therapy, tPA. ) of The National Institutes of Health (NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. ). Receipt of the entire grant award is contingent upon the achievement of certain research milestones. George (Joe) Cox, Ph.D., company president and principal investigator for the grant, stated, "We are grateful to receive continued support from NINDS for our long-acting beta interferon program. With previous funding from NINDS we developed a novel beta interferon analog that has a longer duration of action and more potent biological activity than existing beta interferon products in animals. The new grant award will be used to perform preclinical studies required by the Food and Drug Administration for filing an Investigational New Drug application to begin testing our long-acting beta interferon analog in people. Recombinant beta interferon products have annual worldwide sales of approximately $5 billion, primarily from use of the drugs to treat Multiple Sclerosis. Multiple Sclerosis is a debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction neurological disease that affects approximately 400,000 people in the United States and 2.5 million people worldwide. Current commercial beta interferon products are only partially effective and are inconvenient to use because they must be injected frequently, typically for the life of the patient. Our long-acting beta interferon analog was designed to provide patients with a more efficacious and easier to use product." The NIH SBIR program is a peer-reviewed grant program that provides research support to small businesses to discover and develop innovative biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. products for the treatment of serious unmet medical needs. Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties for the treatment of hematopoietic hematopoietic /he·ma·to·poi·et·ic/ (-poi-et´ik) 1. pertaining to hematopoiesis. 2. an agent that promotes hematopoiesis. hematopoietic 1. pertaining to or affecting the formation of blood cells. and endocrine disorders, cancer and infectious diseases. For more information, visit http://www.bolderbio.com or call 303/420-4420, ext. 202. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion